Proceedings of the 13th International Conference on Thrombosis and Hemostasis Issues in Cancer, 2026
Vol. 5 No. s1 (2026)
Thromboprophylaxis in primary brain cancer
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Published: 16 April 2026
0
Views
0
Downloads
Authors
Venous thromboembolism represents a major source of morbidity and mortality in patients with cancer. Patients with intracranial malignancies, notably high-grade glioma, experience a particularly elevated thrombotic risk. At the same time, these patients are uniquely vulnerable to intracranial hemorrhage, which may occur spontaneously during the disease course even without exposure to anticoagulant therapy. This competing risk profile presents a substantial clinical challenge, as measures designed to avert life-threatening thromboembolic incidents may concurrently elevate the risk of catastrophic intracranial hemorrhage. Consequently, the role of thromboprophylaxis in patients with intracranial tumors remains uncertain. In this review, we critically assess the available evidence on thromboprophylaxis in this population, addressing its risks and potential benefits across diverse clinical settings.
Downloads
Download data is not yet available.
Citations
1. Falanga A, Brenner B, Khorana AA, Francis CW. Thrombotic complications in patients with cancer: Advances in pathogenesis, prevention, and treatment-A report from ICTHIC 2021. Res Pract Thromb Haemost 2022;6:e12744. DOI: https://doi.org/10.1002/rth2.12744
2. Sørensen HT, Pedersen L, van Es N, et al. Impact of venous thromboembolism on the mortality in patients with cancer: a population-based cohort study. Lancet Reg Health Eur 2023;34:100739. DOI: https://doi.org/10.1016/j.lanepe.2023.100739
3. Rasmussen BK, Hansen, S, Laursen RJ, et al. Epidemiology of glioma: clinical characteristics, symptoms and predictors of glioma grade I-IV in the Danish Neuro-Oncology Registry. J Neurooncol 2017;135:571-9. DOI: https://doi.org/10.1007/s11060-017-2607-5
4. Khorana AA, Mackman N, Falanga A, et al. Cancer-associated venous thromboembolism. Nat Rev Dis Primers 2022;8:11. DOI: https://doi.org/10.1038/s41572-022-00336-y
5. Kapteijn MY, Bakker N, Koekkoek JAF, et al. Venous thromboembolism in patients with glioblastoma: molecular mechnisms and clinical implications. Thromb Haemost 2025;125:421-34. DOI: https://doi.org/10.1055/s-0044-1789592
6. Mantia C, Uhlmann EJ, Puligandla M, et al. Predicting the higher rate of intracranial hemorrhage in glioma patients receiving therapeutic enoxaparin. Blood 2017;129:3379-85. DOI: https://doi.org/10.1182/blood-2017-02-767285
7. Shi Y, Kang X, Ge Y, et al. The molecular signature and prognosis of glioma with preoperative intratumoral hemorrhage: a retrospective cohort analysis. BMC Neurol 2024;24:202. DOI: https://doi.org/10.1186/s12883-024-03703-2
8. Kaptein FHJ, Stals MAM, Kapteijn MY, et al. Incidence and determinants of thrombotic and bleeding complications in patients with glioblastoma. J Thromb Haemost 2022;20:1665-73. DOI: https://doi.org/10.1111/jth.15739
9. Jenkins EO, Schiff D, Mackman N, Key NS. Venous thromboembolism in malignant gliomas. J Thromb Haemost 2010;8:221-7. DOI: https://doi.org/10.1111/j.1538-7836.2009.03690.x
10. Unruh D, Schwarze SR, Khoury L, et al. Mutant IDH1 and thrombosis in gliomas. Acta Neuropathol 2016;132:917-30. DOI: https://doi.org/10.1007/s00401-016-1620-7
11. Riedl J, Preusser M, Nazari PM, et al. Podoplanin expression in primary brain tumors induces platelet aggregation and increases risk of venous thromboembolism. Blood 2017;129:1831-9. DOI: https://doi.org/10.1182/blood-2016-06-720714
12. Thaler J, Preusser M, Ay C, et al. Intratumoral tissue factor expression and risk of venous thromboembolism in brain tumor patients. Thromb Res 2013;131:162-5. DOI: https://doi.org/10.1016/j.thromres.2012.09.020
13. Tawil N, Bassawon R, Meehan B, et al. Glioblastoma cell populations with distinct oncogenic programs release podoplanin as procoagulant extracellular vesicles. Blood Adv 2021;5:1682-94. DOI: https://doi.org/10.1182/bloodadvances.2020002998
14. Bayona C, Ranđelović T, Ochoa I. Tumor microenvironment in glioblastoma: the central role of the hypoxic-necrotic core. Cancer Lett 2025:218216. DOI: https://doi.org/10.1016/j.canlet.2025.218216
15. Zhang R, Yao Y, Gao H, Hu X. Mechanisms of angiogenesis in tumour. Front Oncol 2024;14:1359069. DOI: https://doi.org/10.3389/fonc.2024.1359069
16. Mulder FI, Horváth-Puhó E, van Es N, et al. Venous thromboembolism in cancer patients: a population-based cohort study. Blood 2021;137:1959-69. DOI: https://doi.org/10.1182/blood.2020007338
17. Veiga VC, Peres SC, Ostolin T, et al. Incidence of venous thrombo thromboembolism and bleeding in patients with malignant central nervous system neoplasm: systematic review and meta-analysis. PLoS One 2024;19:e0304682. DOI: https://doi.org/10.1371/journal.pone.0304682
18. Cote DJ, Smith TR. Venous thromboembolism in brain tumor patients. J Clin Neurosci 2016;25:13-8. DOI: https://doi.org/10.1016/j.jocn.2015.05.053
19. Hoberstorfer T, Ay C, Riedl J. Mechanisms and treatment of venous thromboembolism in patients with brain cancer: a narrative review. J Thromb Haemost 2026;24:343-53. DOI: https://doi.org/10.1016/j.jtha.2025.10.022
20. Khorana AA, Kuderer NM, Culakova E, et al. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 2008;111:4902-7. DOI: https://doi.org/10.1182/blood-2007-10-116327
21. Ay C, Dunkler D, Marosi C, et al. Prediction of venous thromboembolism in cancer patients. Blood 2010;116:5377-82. DOI: https://doi.org/10.1182/blood-2010-02-270116
22. Burdett KB, Unruh D, Drumm M, et al. Determining venous thromboembolism risk in patients with adult-type diffuse glioma. Blood 2023;141:1322-36. DOI: https://doi.org/10.1182/blood.2022017858
23. Edwin NC, Khoury MN, Sohal D, et al. Recurrent venous thromboembolism in glioblastoma. Thromb Res 2016;137:184-8. DOI: https://doi.org/10.1016/j.thromres.2015.11.027
24. Mahé I, Frère C, Pernod G, et al. Management of venous thromboembolic disease in patients with malignant brain tumours. Arch Cardiovasc Dis 2024;117:60-71. DOI: https://doi.org/10.1016/j.acvd.2023.11.004
25. Giustozzi M, Proietti G, Becattini C, et al. ICH in primary or metastatic brain cancer patients with or without anticoagulant treatment: a systematic review and meta-analysis. Blood Adv 2022;6:4873-83. DOI: https://doi.org/10.1182/bloodadvances.2022008086
26. Moik F, Posch F, Zielinski C, et al. Direct oral anticoagulants compared to low-molecular-weight heparin for the treatment of cancer-associated thrombosis: Updated systematic review and meta-analysis of randomized controlled trials. Res Pract Thromb Haemost 2020;4:550-61. DOI: https://doi.org/10.1002/rth2.12359
27. Iyengar V, Agrawal S, Chiasakul T, et al. Comparison of direct oral anticoagulants versus low-molecular-weight heparin in primary and metastatic brain cancers: a meta-analysis and systematic review. J Thromb Haemost 2024;22:4230429. DOI: https://doi.org/10.1016/j.jtha.2023.10.011
28. Hamulyák EN, Wang TF, Baumann Kreuziger L, et al. Intracranial hemorrhage in patients with primary brain cancer receiving anticoagulation (ABC Study). Blood Vessel Thrombs Hemost 2026;30:100140. DOI: https://doi.org/10.1016/j.bvth.2026.100140
29. Hamulyák EN, Wang TF, Kreuziger LB, et al. Multinational cohort study of intracranial hemorrhage in patients with brain metastases receiving anticoagulation. Haematologica 2025;110:1417-21. DOI: https://doi.org/10.3324/haematol.2024.286973
30. Key NS, Khorana AA, Kuderer NM, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO Guideline Update. J Clin Oncol 2023;41:3063-71. DOI: https://doi.org/10.1200/JCO.23.00294
31. Lyman GH, Carrier M, Ay C, et al. American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. Blood Adv 2021;5:927-974. DOI: https://doi.org/10.1182/bloodadvances.2021004734
32. Farge D, Frere C, Connors JM, et al. 2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19. Lancet Oncol 2022;23:e334-7.
33. Falanga A, Ay C, Di Nisio M, et al. Venous thromboembolism in cancer patients: ESMO Clinical Practice Guideline. Ann Onco. 2023;34:452-67. DOI: https://doi.org/10.1016/j.annonc.2022.12.014
34. Perry JR, Julian JA, Laperriere NJ, et al. PRODIGE: a randomized placebo-controlled trial of dalteparin low-molecular-weight heparin thromboprophylaxis in patients with newly diagnosed malignant glioma. J Thromb Haemost 2010;8:1959-65. DOI: https://doi.org/10.1111/j.1538-7836.2010.03973.x
35. Carrier M, Abou-Nassar K, Mallick R, et al. Apixaban to prevent venous thromboembolism in patients with cancer. N Engl J Med 2019;380:711-9. DOI: https://doi.org/10.1056/NEJMoa1814468
36. Khorana AA, Soff GA, Kakkar AK, et al. Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer. N Engl J Med 2019;380:720-8. DOI: https://doi.org/10.1056/NEJMoa1814630
37. Cornell RF, Goldhaber SZ, Engelhardt BG, et al. Primary prevention of venous thromboembolism with apixaban for multiple myeloma patients receiving immunomodulatory agents. Br J Haematol 2020;190:555-61. DOI: https://doi.org/10.1111/bjh.16653
38. Codreanu C, Elling T, Veeger NJGM, et al. A systematic review of direct oral anticoagulants for thromboprophylaxis in multiple myeloma. Res Pract Thromb Haemost 2025;9:102865. DOI: https://doi.org/10.1016/j.rpth.2025.102865
39. Adrianzen-Herrera D, Giorgio K, Walker RF, et al. Bleeding risk from anticoagulant thromboprophylaxis in patients with multiple myeloma: a MarketScan analysis. Res Pract Thromb Haemost 2024;8:102418. DOI: https://doi.org/10.1016/j.rpth.2024.102418
40. Liu D, Song D, Ning W, et al. Efficacy and safety of prophylaxis for venous thromboembolism in brain neoplasm patients undergoing neurosurgery: a systematic review and Bayesian network meta-analysis. J Thromb Thrombolysis 2023;55:710-20. DOI: https://doi.org/10.1007/s11239-023-02780-3
41. Zhang Z, Cai H, Vleggeert-Lankamp CLA. Thromboembolic prophylaxis in neurosurgical practice: a systematic review. Acta Neurochir (Wien) 2023;165:3119-35. DOI: https://doi.org/10.1007/s00701-023-05792-3
42. Agnelli G, Piovella F, Buoncristiani P, et al. Enoxaparin plus compression stockings compared with compression stockings alone in the prevention of venous thromboembolism after elective neurosurgery. N Engl J Med 1998;339:80-5. DOI: https://doi.org/10.1056/NEJM199807093390204
43. Zhang Z, Marcano A, Huisman MV, et al. Intermittent compression devices as antithrombotic strategy in neurosurgical interventions: a prospective randomized controlled trial (Trial In Prevention of Post-Operative ThromboEmbolic Events). J Thromb Haemost 2025;23:3561-8. DOI: https://doi.org/10.1016/j.jtha.2025.04.019
44. Bosch FTM, Mulder FI, Kamphuisen PW, et al. Primary thromboprophylaxis in ambulatory cancer patients with a high Khorana score: a systematic review and meta-analysis. Blood Adv 2020;4:5215-25. DOI: https://doi.org/10.1182/bloodadvances.2020003115
45. Eisele A, Seystahl K, Rushing EJ, et al. Venous thromboembolic events in glioblastoma patients: An epidemiological study. Eur J Neurol 2022;29:2386-97. DOI: https://doi.org/10.1111/ene.15404
46. Suleman A, Wine R, Carrier M, Hicks LK. The risk of venous thromboembolism in primary central nervous system lymphoma: a systematic review and meta-analysis. Res Pract Thromb Haemost 2024;8:102507. DOI: https://doi.org/10.1016/j.rpth.2024.102507
47. Abdulla A, Davis WM, Ratnaweera N, et al. A meta-analysis of case fatality rates of recurrent venous thromboembolism and major bleeding in patients with cancer. Thromb Haemost 2020;120:702-13. DOI: https://doi.org/10.1055/s-0040-1708481
48. Zwicker JI, Karp Leaf R, Carrier M. A meta-analysis of intracranial hemorrhage in patients with brain tumors receiving therapeutic anticoagulation. J Thromb Haemost 2016;14:1736-40. DOI: https://doi.org/10.1111/jth.13387
49. Mahé I, Carrier M, Mayeur D, et al. Extended reduced-dose apixaban for cancer-associated venous thromboembolism. N Engl J Med 2025;392:1363-73. DOI: https://doi.org/10.1056/NEJMoa2416112
50. Mahé I, Chapelle C, Girard P, et al. Predictors of clinically relevant bleeding during extended anticoagulation for cancer-associated venous thromboembolism (API-CAT): a post-hoc analysis of a randomised, non-inferiority trial. Lancet Haematol 2026;13:e41-8. DOI: https://doi.org/10.1016/S2352-3026(25)00291-1
51. Cohen O, Santagata D, Ageno W. Novel horizons in anticoagulation: the emerging role of factor XI inhibitors across different settings. Haematologica 2024;109:3110-24. DOI: https://doi.org/10.3324/haematol.2023.283682
52. Carney BJ, Uhlmann EJ, Puligandla M, et al. Anticoagulation after intracranial hemorrhage in brain tumors: Risk of recurrent hemorrhage and venous thromboembolism. Res Pract Thromb Haemost 2020;4:860-5. DOI: https://doi.org/10.1002/rth2.12377
53. Leader A, Wilcox JA, Zwicker JI. How I treat acute venous thromboembolism in patients with brain tumors. Blood 2024;144:1781-90. DOI: https://doi.org/10.1182/blood.2023023450
54. Djulbegovic B, Boylan A, Kolo S, et al. Converting IMPROVE bleeding and VTE risk assessment models into a fast-and-frugal decision tree for optimal hospital VTE prophylaxis. Blood Adv 2024;8:3214-24. DOI: https://doi.org/10.1182/bloodadvances.2024013166
How to Cite
1.
Hamulyák EN, Hutten BA, van Es N. Thromboprophylaxis in primary brain cancer. Bleeding Thromb Vasc Biol [Internet]. 2026 Apr. 16 [cited 2026 Apr. 17];5(s1). Available from: https://www.btvb.org/btvb/article/view/455
Copyright (c) 2026 The Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
